Dec 01, 2022 / 03:30PM GMT
Umer Raffat - Evercore ISI Institutional Equities, Research Division - Senior MD & Senior Analyst of Equity Research
Hello, everyone. Pleasure to have Biogen management join us right after Merck. And there's a lot to talk about, but let me turn it over to you, Mike, to kick things off.
Michael R. McDonnell - Biogen Inc. - Executive VP & CFO
Excellent. Thank you very much, Umer, and thank you for having us today, and thank you to everyone for joining us. Priya and I are very happy to be with you.
Before we begin, I do want to just point out that we -- Priya and I will be making some forward-looking statements, and those are based on current expectations and believe actual results could differ, and I would encourage you to refer to our risk factors in our SEC filings.
Here at Biogen, we're very focused on executing and delivering the best results that we can. We last reported in October. And at that time, we raised our guidance on both the top line and the bottom line for the second time this year. Our guidance back in October was on the
Biogen Inc at Evercore ISI HealthCONx Conference (Virtual) Transcript
Jan 22, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers